Tags: Repurposing

announcements

$7.1 Million in New Funding Illustrates the ADDF's Strong Support of a Diverse Pipeline

The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.

blog

Alzheimer's and Inflammation: The BEACON Study

Dr. Paula Grammas writes about the role brain blood vessels may play in Alzheimer's disease.

announcements

19th International Conference on Alzheimer's Drug Discovery Highlights Multiple Approaches

The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.

announcements

$2.3 Million in New Funding Focused on Novel Biomarkers and Treatments

The Alzheimer's Drug Discovery Foundation (ADDF) announces funding for a novel biomarker and two Phase I clinical studies.

blog

Trial of First Broad-Spectrum Drug for Neurodegeneration Seeking Volunteers

ADDF grantee Dr. Raymond Scott Turner is recruiting patients for a phase 2 trial of nilotinib—a leukemia drug being tested for treating Alzheimer’s.

announcements

ADDF-Funded Scientists Discover Two Repurposed Drugs With Promise for Alzheimer's and FTD

A team of scientists from the Medical Research Council (MRC) in the UK have found two drugs, which block brain cell death and prevent neurodegeneration in preclinical studies. Their findings were published today in Brain.

blog

Closing in on a Cure: Dr. Michela Gallagher and AGB101

Dr. Michela Gallagher of Agenebio is developing AGB101, which can potentially prevent mild cognitive impairment from progressing to Alzheimer's disease.

announcements

New Clinical Trial Will Test Cancer Drug as Alzheimer's Treatment

Dr. Howard Fillit, the ADDF's Founding Executive Director and Chief Science Officer, says: "The ADDF is proud to support a clinical trial that holds such promise for Alzheimer's patients. This funding is part of our wider initiative to use the knowledge gained from cancer research to advance effective treatments for Alzheimer's."

announcements

Grantees at Lou Rovo Center for Brain Health Recruiting for New Alzheimer's Disease Trial

Cleveland Clinic Lou Ruvo Center for Brain Health is recruiting participants for a trial to determine if treatment with rasagiline improves brain glucose metabolism and memory.

announcements

New Approach to Delay Alzheimer’s Dementia Onset to Be Tested in Phase-3 Clinical Trial

The ADDF announced today a grant to AgeneBio in support of an FDA-registered Phase 3 clinical trial of AGB101, a new therapeutic treatment for amnestic mild cognitive impairment.